RT Book, Section
A1 Holle, Lisa M.
A1 Clement, Jessica M.
A1 Davis, Lisa E.
A2 DiPiro, Joseph T.
A2 Yee, Gary C.
A2 Posey, L. Michael
A2 Haines, Stuart T.
A2 Nolin, Thomas D.
A2 Ellingrod, Vicki
SR Print(0)
ID 1191342176
T1 Colorectal Cancer
T2 Pharmacotherapy: A Pathophysiologic Approach, 11e
YR 2020
FD 2020
PB McGraw-Hill Education
PP New York, NY
SN 9781260116816
LK accesspharmacy.mhmedical.com/content.aspx?aid=1191342176
RD 2024/04/20
AB Update  SummaryThe  following  updates  to  this  chapter  were  made  on  February  7,  2021:Metastatic  Disease  Initial  Therapy  section  and  Table  147-6  updated:  Removed  fluorouracil/leucovorin  +  bevacizumab  and  capecitabine  +  bevacizumab  as  no  longer  recommended  as  first-line  therapy  in  patients  appropriate  for  intensive  therapy;  added  pembrolizumab  for  patients  with  dMMR/MSI-H  appropriate  for  intensive  therapy;  updated  dosing  intervals  for  checkpoint  inhibitors;  and  added  trastuzumab  +  [pertuzumab  or  lapatinib]  for  patients  not  appropriate  for  intensive  therapy  with  HER  amplified  and  RAS  and  BRAF  WTTable  147-7  in  Metastatic  Disease:  Second-Line  and  Subsequent  Therapy  section  updated:  Removed  binimetinib  as  no  longer  recommended  in  combination  with  encorafenib  if  BRAF  V600  mutation  positive;  removed  section  on  second-line  options  following  first-line  fluorouracil-based  regimens;  and  added  regimens  for  BRAF  V600  mutation  mutation-positive  patients  for  second-  or  subsequent-line  regimens